Generics sector fights for seat at table in UK pricing negotiations

The British Generic Manufacturers Association (BGMA) is seeking a judicial review of the decision on the part of the UK government to exclude it from negotiations over a future pricing framework.

The UK is about to enter into discussions with the Association of the British Pharmaceutical Industry (ABPI) to agree on a new voluntary scheme for branded medicine pricing (VPAS).

The scheme ensures that the overall cost of innovative medicines is capped, but unexpectedly high demand for such products in recent years has led to high rebates being paid by the industry.